Company Overview
Snapshot
Founded in December 2017 by Ziv Menshes, Or Hazan, Dr. Yonatan Demma, and Ran Eliaz, CardioVia operates with 1–10 employees. The company has secured $55K across two funding rounds from NGT3. In April 2025, CardioVia announced FDA clearance for its ViaOne system, marking a significant milestone in minimally invasive cardiac access.
Business overview
CardioVia is a medical device company focused on developing the ViaOne system, a technology designed for minimally invasive access to the outer surface of the heart (pericardial space). This system aims to provide a safer entry route for treating prevalent cardiovascular diseases such as tamponade, effusion, and arrhythmias. The company's core technology ensures no needle exposure to the heart during the procedure, synchronizing with heartbeats for controlled penetration without puncturing the heart muscle. CardioVia serves the healthcare industry, specifically targeting medical device and treatment markets within the Health Tech & Life Sciences sector.
Strategic signal
In April 2025, CardioVia received FDA clearance for its ViaOne system. This regulatory approval is a critical validation of the company's technology, signaling to investors and the medical community that ViaOne is ready for broader clinical adoption. This milestone positions CardioVia to potentially transform minimally invasive cardiac access procedures, offering a safer and more controlled approach to treating cardiovascular conditions.
Log in to access full profile ›Company Intelligence Q&A
- What is CardioVia's primary product?
- CardioVia's primary product is the ViaOne system, a medical device designed for minimally invasive access to the outer surface of the heart.
- When was CardioVia founded and by whom?
- CardioVia was founded in December 2017 by Ziv Menshes, Or Hazan, Dr. Yonatan Demma, and Ran Eliaz.
- Has CardioVia received any significant regulatory approvals?
- Yes, in April 2025, CardioVia announced FDA clearance for its ViaOne system, opening new possibilities in minimally invasive heart surface treatments.
- What is the total capital raised by CardioVia?
- CardioVia has raised $55K across two funding rounds.
- Has CardioVia received any grants?
- In August 2019, CardioVia received a grant of $55,000 from the EU Horizon 2020 research and innovation program.